3,5-dibromotyrosine has been researched along with Apoplexy in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cao, W; Glushakov, A; Martynyuk, AE; Mecca, AP; Seubert, CN; Shah, HP; Shi, P; Sumners, C | 1 |
| Dennis, DM; Glushakov, AV; Kagiyama, T; Martynyuk, AE; Ozcan, MS; Phillips, MI; Roose, B; Seubert, CN; Sumners, C | 1 |
2 other study(ies) available for 3,5-dibromotyrosine and Apoplexy
| Article | Year |
|---|---|
Halogenated aromatic amino acid 3,5-dibromo-D: -tyrosine produces beneficial effects in experimental stroke and seizures.
Topics: Animals; Blood Pressure; Brain; Caspase 3; Disease Models, Animal; Endothelin-1; Epilepsy; Heart Rate; Hydrocarbons, Brominated; Infarction, Middle Cerebral Artery; Male; Motor Activity; Pentylenetetrazole; Rats; Rats, Sprague-Dawley; Severity of Illness Index; Stroke; Tyrosine | 2011 |
Neuroprotective action of halogenated derivatives of L-phenylalanine.
Topics: Animals; Disease Models, Animal; In Vitro Techniques; Infarction, Middle Cerebral Artery; L-Lactate Dehydrogenase; Male; Neurons; Neuroprotective Agents; Patch-Clamp Techniques; Phenylalanine; Rats; Rats, Sprague-Dawley; Receptors, Glutamate; Stroke; Synaptic Transmission; Tyrosine | 2004 |